[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interleukin-6\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interleukin-6":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100431190","phase-4-opioid-free-anesthesia-analgesia-strategy-and-surgical-stress-in-elective-open-abdominal-aortic-aneurysm-repair-100431190",false,"NCT04894864","Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair","Effect of a Perioperative Opioid Free Anesthesia-Analgesia (OFA-A) Strategy on Surgical Stress Response in Elective Open Abdominal Aortic Aneurysm Repair: A Prospective Randomized Study","Inclusion Criteria:\n\n1. Patient Consent\n2. Age between 40 and 85 years old\n3. Patients undergoing Elective Open Abdominal Aortic Infrarenal Aneurysm Repair\n\nExclusion Criteria:\n\n1. Immunocompromised patients\n2. Patients with active infection\n3. Reoperation on the aorta\n4. Inflammatory bowel Disease\n5. Malignancy\n6. Chronic Inflammatory conditions (e.g. Rheymatoid arthritis, Psoriatic arthritis)\n7. Chronic corticosteroid or immunosuppressive drug use\n8. Intraoperative transfusion with \\>2 units of packed Red Blood Cells","ALL","40 Years","85 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Open Abdominal Aortic Aneurysm (AAA) repair is a high-risk surgical procedure accompanied by intense endocrine and metabolic responses to surgical stress, with subsequent activation of the inflammatory cascade, cytokine and acute-phase protein release, and bone marrow activation. There is a proven correlation of surgical stress, which patients undergoing open AAA repair are subjected to, with patient outcome, morbidity\u002Fmortality, intensive care unit stay and overall length of stay. Modern general anesthetic techniques have been revised and rely on perioperative multimodal anesthetic and analgesic strategies for improved overall patient outcome. Based on this context of a multimodal anesthetic technique and having taken into consideration the international \"opioid-crisis\" epidemic, an Opioid Free Anesthesia-Analgesia (OFA-A) strategy started to emerge. It is based on the administration of a variety of anesthetic\u002Fanalgesic agents with different mechanisms of action, including immunomodulating and anti-inflammatory effects.\n\nOur basic hypothesis is that the implementation of a perioperative multimodal OFA-A strategy, involving the administration of pregabalin, ketamine, dexmedetomidine, lidocaine, dexamethasone, dexketoprofen, paracetamol and magnesium sulphate, will lead to attenuation of surgical stress response compared to a conventional Opioid-Based Anesthesia-Analgesia (OBA-A) strategy. Furthermore, the anticipated attenuation of the inflammatory response, is pressumed to be associated with equal or improved analgesia, compared to a perioperative OBA-A technique.",[27,28,29,30,31,32,33,34],"Elective Surgical Procedures","Postoperative Pain","Anesthesia","Opioid Use","Abdominal Aortic Aneurysm Without Rupture","Vascular Surgical Procedure","Interleukin 6","Immunomodulators",[36,37,38,39,40,41,42],"Opioid-free Anesthesia-Analgesia","Cytokines","Opioid-based Anesthesia-Analgesia","Haemodynamic Stability","Open Abdominal Aortic Aneurysm Repair","Immunomodulation","Inflammatory Markers","RECRUITING","2026-06-13",{"date":46,"type":47},"2026-06-16","ACTUAL",{"date":49,"type":47},"2020-10-08",{"date":51,"type":21},"2027-09-01",{"name":53,"class":54},"University of Crete","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":64,"maxAge":17,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100623423","phase-4-supplementary-kelulut-honey-therapy-in-juvenile-open-angle-glaucoma-effects-on-il-6-rnfl-and-dry-eye-100623423","NCT07396441","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye.","HONEY-JOAG","Inclusion Criteria:\n\nJOAG patients age 15 years old and above until 40 years old at the time of diagnosis Compliant to conventional treatment achieved target intraocular pressure\n\nExclusion Criteria:\n\nPatients with allergy to honey or honey-based products OCT signal less than 6\u002F10 Concurrent retinal diseases and other optic neuropathies Systemic neurodegenerative disease Systemic comorbidities such as diabetes mellitus and autoimmune diseases Patients on other honey-based products for the last 3 months Patient who consumes honey-based products during the study duration of 3 months (monitoring via honey-diary, return of the used sachet during the follow up visits) Patients on anti-oxidants, traditional medications or herbal products for the last 3 months Topical usage of steroids, systemic steroids and non-steroidal anti-inflammatory drugs.\n\nSepsis Compliance less than 75%.","15 Years",{"count":66,"type":21},60,[24],"The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.",[70,71,33,72,73],"Juvenile Open Angle Glaucoma","Dry Eye Disease (DED)","Retinal Nerve Fiber Layer Thickness","HbA1c Level","2026-02-03",{"date":76,"type":47},"2026-02-09",{"date":78,"type":47},"2026-01-15",{"date":80,"type":21},"2026-06-30",{"name":82,"class":54},"Universiti Sains Malaysia",4,"Interleukin-6"]